WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address ...
Presentation to Highlight Phase 1 REM-422 ACC Data Demonstrating 43% Overall Response Rate and Durable Responses Exceeding One Year with Favorable Safety Results WATERTOWN, Mass., July 16, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results